Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The source filing: CRISPR Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:48 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204188
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating activities: | ||
| Net loss | $(122,931) | $(135,996) |
| Reconciliation of net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 4,319 | 4,736 |
| Equity-based compensation | 16,324 | 20,212 |
| Other non-cash items, net | 8,800 | 2,253 |
| Changes in: | ||
| Accounts receivable | — | 25,000 |
Item 1. Financial Statements
FAQ
- What is CRISPR Therapeutics's D&A?
- CRISPR Therapeutics (CRSP) reported D&A of $4.32M in Q1 2026.
- How has CRISPR Therapeutics's D&A changed year-over-year?
- CRISPR Therapeutics's D&A decreased by 8.8% year-over-year, from $4.74M to $4.32M.
- What is the long-term trend for CRISPR Therapeutics's D&A?
- Over 4 years (2021 to 2025), CRISPR Therapeutics's D&A has grown at a 2.1% compound annual growth rate (CAGR), from $17.95M to $19.48M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about CRISPR Therapeutics's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude